Cas:60386-55-2 3-Isopropyl-1,2-cyclopentanedione manufacturer & supplier

Chemical Name:3-Isopropyl-1,2-cyclopentanedione

CAS.NO:60386-55-2

Synonyms:3-Isopropyl-1,2-cyclopentanedione

Molecular Formula:C₈H₁₂O

Molecular Weight:140

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Isopropyl-1,2-cyclopentanedione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Isopropyl-1,2-cyclopentanedione physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Isopropyl-1,2-cyclopentanedione Use and application,3-Isopropyl-1,2-cyclopentanedione technical grade,usp/ep/jp grade.

Related News: After testing, our quality assurance staff confirms that everything has been performed correctly in accordance with GMP from manufacturing of API to quality testing. 3-Isopropyl-1,2-cyclopentanedione manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 3-Isopropyl-1,2-cyclopentanedione supplier Vietnam backtracked on Saturday and narrowed its restrictions to most flights from mainland China. 3-Isopropyl-1,2-cyclopentanedione vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 3-Isopropyl-1,2-cyclopentanedione factory The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.